Stock NEWBRY NEWBURY PHARMACEUTICALS AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Newbury Pharmaceuticals AB

Equities

NEWBRY

SE0015244884

Market Closed - Nasdaq Stockholm
Other stock markets
 11:22:47 2024-06-07 am EDT 		5-day change 1st Jan Change
3.22 SEK +9.52% Intraday chart for Newbury Pharmaceuticals AB +5.92% +4.89%
Apr. 10 Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Feb. 22 Newbury Pharmaceuticals Secures SEK9 Million Sales Order MT

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Drug Retailers

1st Jan change Capi. Investor Rating ESG Refinitiv
NEWBURY PHARMACEUTICALS AB Stock Newbury Pharmaceuticals AB
+4.89% 7.41M - -
AIN HOLDINGS INC. Stock Ain Holdings Inc.
+33.06% 1.33B -
QOL HOLDINGS CO., LTD. Stock Qol Holdings Co., Ltd.
-12.43% 346M -
NIHON CHOUZAI CO.,LTD. Stock NIHON CHOUZAI Co.,Ltd.
-0.07% 267M -
SALUS, LJUBLJANA, D. D. Stock SALUS, Ljubljana, d. d.
+10.56% 227M - -
PETMED EXPRESS, INC. Stock PetMed Express, Inc.
-42.59% 88.52M
C
GREEN CROSS HEALTH LIMITED Stock Green Cross Health Limited
-14.68% 81.59M - -
MEDICAL IKKOU GROUP CO.,LTD. Stock Medical Ikkou Group Co.,Ltd.
+26.03% 62.4M - -
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. NEWBRY Stock
  4. Ratings Newbury Pharmaceuticals AB